NeoGenomics Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $188 million, up 12% year-over-year, with a 4% sequential increase from Q2.

Clinical Revenue: Grew 18% year-over-year, driven by strong test volumes and share gains.

Adjusted EBITDA: $12.2 million, marking the ninth consecutive quarter of positive earnings.

Total Test Volumes: Increased by 15% in Q3, with average revenue per test (AUP) rising by 3%.

Cash Flow from Operations: Positive $9 million, with total cash at $164 million.

Nonclinical Revenue: Declined due to lower pharma and biotech customer revenue, accounting for less than 9% of total revenue.

2Strategic Updates and Business Highlights

Record Clinical Volumes: Continued growth in clinical business, with significant contributions from next-generation sequencing (NGS) and minimal impact from nonclinical revenue declines.

Acquisition of Pathline: Integration is on track, enhancing presence in the Northeast U.S. and expected to drive growth and operational efficiencies starting in 2026.

RaDaR ST Assay: Favorable court ruling allows for broader commercialization in 2026, with initial launches in pharma and expected clinical launch in Q1 2026.

NGS Growth: NGS revenues increased by 24%, driven by five new products launched in 2023, contributing significantly to clinical revenue.

3Forward Guidance and Outlook

2025 Revenue Guidance: Reiterating guidance of $720 million to $726 million, representing 9% to 10% growth over 2024.

Adjusted EBITDA Guidance: Expected to be in the range of $41 million to $44 million, with a projected net loss of $116 million to $108 million, reflecting a significant increase compared to 2024.

2026 Expectations: Anticipated continued growth in clinical performance, particularly in NGS and MRD markets, with a focus on expanding the sales force and enhancing customer experience.

4Bad News, Challenges, or Points of Concern

Nonclinical Revenue Decline: The nonclinical segment continues to face challenges, particularly in pharma revenue, which is expected to remain soft through 2026.

Increased Operating Expenses: Total operating expenses rose by 12%, driven by higher compensation costs and impairment charges related to the planned sale of Trapelo.

Market Competition: Ongoing competitive pressures in the NGS space, with a need to maintain differentiation through product offerings and customer experience.

5Notable Q&A Insights

RaDaR Adoption: Positive reception from community oncologists following the court ruling, with expectations for revenue growth in pharma partnerships and clinical settings.

NGS Volume Growth: Primarily driven by volume rather than price increases, indicating strong market penetration.

Sales Force Expansion: The expansion is expected to enhance customer engagement and drive growth, particularly in community oncology settings.

LIMS and Epic Integration: Expected to streamline operations and improve customer experience, with benefits anticipated in 2026 and beyond. Overall, NeoGenomics reported a strong quarter with significant growth in clinical revenue and strategic advancements, particularly in NGS and MRD testing. However, challenges remain in the nonclinical segment and competitive landscape, necessitating continued focus on operational excellence and customer experience.